Meningitis primary prevention: Difference between revisions
(Created page with "{{Meningitis}} {{CMG}}; '''Associate Editor(s)-In-Chief:''' {{CZ}} ==Overview== ==References== {{reflist|2}} {{WikiDoc Help Menu}} {{WikiDoc Sources}} [[Category:Disease...") |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Immunization== | |||
All current vaccines target only bacterial meningitis. | |||
Vaccinations against ''[[Haemophilus influenzae]]'' ([[Hib vaccine|Hib]]) have decreased early childhood meningitis significantly.<ref name="pmid10756001">{{cite journal |author=Peltola H |title=Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates |journal=Clin. Microbiol. Rev. |volume=13 |issue=2 |pages=302-17 |year=2000 | url=http://cmr.asm.org/cgi/content/full/13/2/302 |pmid=10756001 |accessdate=2007-09-03}}</ref> | |||
Vaccines against type A and C ''[[Neisseria meningitidis]]'', the kind that causes most disease in preschool children and teenagers in the United States, have also been around for a while. Type A is also prevalent in sub-Sahara Africa and W135 outbreaks have affected those on the Hajj pilgrimage to Mecca. | |||
A vaccine called ''[[MeNZB]]'' for a specific strain of type B Neisseria meningitidis prevalent in New Zealand has completed trials and is being given to many people in the country under the age of 20. There is also a vaccine, MenBVac, for the specific strain of type B meningoccocal disease prevalent in Norway, and another specific vaccine for the strain prevalent in Cuba. | |||
[[Pneumococcal polysaccharide vaccine]] against ''[[Streptococcus pneumoniae]]'' is recommended for all people 65 years of age or older. [[Pneumococcal conjugate vaccine]] is recommended for all newborns starting at 6 weeks - 2 months, according to American Association of Pediatrics (AAP) recommendations. | |||
==References== | ==References== | ||
Revision as of 21:09, 8 February 2012
|
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Immunization
All current vaccines target only bacterial meningitis.
Vaccinations against Haemophilus influenzae (Hib) have decreased early childhood meningitis significantly.[1]
Vaccines against type A and C Neisseria meningitidis, the kind that causes most disease in preschool children and teenagers in the United States, have also been around for a while. Type A is also prevalent in sub-Sahara Africa and W135 outbreaks have affected those on the Hajj pilgrimage to Mecca.
A vaccine called MeNZB for a specific strain of type B Neisseria meningitidis prevalent in New Zealand has completed trials and is being given to many people in the country under the age of 20. There is also a vaccine, MenBVac, for the specific strain of type B meningoccocal disease prevalent in Norway, and another specific vaccine for the strain prevalent in Cuba.
Pneumococcal polysaccharide vaccine against Streptococcus pneumoniae is recommended for all people 65 years of age or older. Pneumococcal conjugate vaccine is recommended for all newborns starting at 6 weeks - 2 months, according to American Association of Pediatrics (AAP) recommendations.
References
- ↑ Peltola H (2000). "Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates". Clin. Microbiol. Rev. 13 (2): 302–17. PMID 10756001. Retrieved 2007-09-03.